Mercy Hospital & Health Services Contact Us
About Mercy
Join Our Team
set font size large set font size medium set font size small
email this page print this page
Adult Clinical Trials Available Banner

Clinical Research Trials Available

The following Clinical Research Trials are available through Mercy.   Additional information can be found at


Infectious Disease 419-251-4919

Clostridium difficille infection (C-Diff) Protocol link
  A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile associated diarrhea
Sepsis Protocol link
  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy
  Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity with Enteric LB1148 (SSAIL Study)
Bacterial Skin Infections Protocol link
  A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized with Bacteremia Due to Staphylococcus Aureus  

PULMONARY 419-251-4919

COPD Protocol link
  A Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV study to evaluate the effect of Aclidinium Bromide on long-term Cardiovascular safety and COPD exacerbations in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD). Phase 4-Tudorza  
  A randomized, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. [DYNAGITO I]

SLEEP 419-251-4919

Narcolepsy Protocol link
Adult A Twelve-week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy.
OSA Protocol link
  A Twelve-week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Subjects with Obstructive Sleep Apnea (OSA).
Narcolepsy or OSA Protocol link
By invitation only  A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apnea (OSA). 

CARDIAC 419-251-4919

Atrial Fibrilation Protocol link
  GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III) 
Cardiac Intervention Protocol link
Leads Product Surveillance Registry
STENT BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - Bioflow-V
Randomized Controlled Trial Clinical Evaluation of the ABSORB™ Bioresorbable Vascular Scaffold (BVS) in the Treatment of Subjects with de novo Native Coronary Artery Lesions
Post-intervention  A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI)

Neurology 419-251-4919

Intervention Protocol link
  Safety and Effectiveness of the Treatment of Wide Neck, Intracranial, Saccular Aneurysms With the Next Generation Neuroform Stent System
  Analysis of Revascularization in Ischemic Stroke With EmboTrap (ARISE II)

Oncology 419-251-4919

Brain Title NCT #
Glioblastoma A Phase II/III Randomized trial of Veliparib or Placebo in combination with adjuvent Temozolomide in newly diagnosed Glioblastoma with MGMT promoter Hypermethylation NCT02152982
Glioma A Phase III Randomized Double Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer Related Fatigue in Patients with High Grade Glioma NCT01781468
Adjuvant A Randomized, Double Blind, Parrellel Group, Placebo Controlled Multi Center Phase III Study to assess the efficacy and safety of Loaparib versus Placebo as Adjuvant Treatment in patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy NCT02032823
Adjuvant A Randomized Phase III Tiral of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node Negative Triple Negative Invasive Breast Cancer NCT02488967
Cancer Control A Randomized Phase III trial of endocrine therapy plus entinostat/placebo in postmenopausal patients with hormone receptor positive advanced breast cancer NCT02115282
Colorectal Randomized phase II study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF mutant Metastatic Colorectal Cancer. NCT02164916
Pancreas A Phase II-R and A Phase III Trial Evaulating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma NCT01013649
Pancreas A Randomized phase II study of perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as therapy for resectable pancreatic adenocarcinoma NCT02562716
Renal Phase III Study: Everolimus for Renal Cancer Ensuing Surgical Therapy NCT01120249
Prostate Androgen Deprivation thereapy and high dose Radiotherapy with or without whole pelvic radiothereapy in unfavorable intermediate or favorable high risk prostate cancer: A Phase III Randomized Trial NCT01368588
Prostate A Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer NCT01949337
Prostate A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer NCT00936390
Prostate Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer NCT01809691
Bladder A Radnomized Phase II Study of co Expression Extrapolation (Coxen) with Neoadjuvant Chemotherapy for localized, muscle invasive bladder cancer NCT02177695
Head and Neck  
Advanced Resected A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer NCT00956007
CLL A Randomized Phase III Study of Ibrutinib (PCI-32765) based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) NCT02048813
Hodgkin Lymphoma Phase II Trial of Response-Adapted therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)    NCT01118026
Multiple Myeloma Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis NCT01408225
PCV Prospective Non International Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices NCT 02252159
Adjuvant Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) NCT02194738
NSCLC A Phase III Double blind trial for surgically resected early stage non small cell lung cancer: Crizotinib versus Placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein  
NSCLC Randomized double blind placebo controlled study of Erlotinib or Placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant Non Small Cell Lung Cancer (NSCLC) NCT02193282
NSNSCLC A Phase III open label randomized study of Atezolizumab (MPDL3280A Anti-PD-L1 Antibody) in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy naïve patients with stage IV non squamous non-small cell lung cancer NCT02366143
NSCLC A Phase III, Open label, Multicenter, randomized study evaluating the efficacy and safety of Atezolizumab (MPDL3280A Anti-PD-L1 Antibody) in combination with caroplatin +paclitaxel or Atexolizumab in combination with Carboplatin + Nab Paclitaxel versus carboplatin + Nab Paclitaxel in chemotherapy naive patients with Stage IV Squamous non small cell lung cancer NCT02367794
Patient Satisfaction  
  Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials  
Cancer Control Prevention  
  A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) NCT01824836
follow us online
facebook youtube

Contact us
Home  |  Sitemap

Disclaimer & Terms of Use  |  Privacy Statement  |  Notice of Privacy Practices
Copyright ©2016 Mercy. Last modified 3/15/2016